← Back to Search

Other

Treatment group A for Prevention of Nausea and Vomiting

Phase 3
Waitlist Available
Research Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up evaluation time points include 1-2 hours, 5-10 hours, and 3 days after the start of the first hr20013 administration, and day 1 of the second hr20013 administration
Awards & highlights

Summary

To evaluate the efficacy and safety of HR20013 for injection for prevention of chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy.

Eligible Conditions
  • Prevention of Nausea and Vomiting

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~evaluation time points include 1-2 hours, 5-10 hours, and 3 days after the start of the first hr20013 administration, and day 1 of the second hr20013 administration
This trial's timeline: 3 weeks for screening, Varies for treatment, and evaluation time points include 1-2 hours, 5-10 hours, and 3 days after the start of the first hr20013 administration, and day 1 of the second hr20013 administration for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Complete response during the overall phase after the start of the first cisplatin administration
Secondary study objectives
Complete protection
Complete response during the acute phase, the delayed phase, >120-168 hours, and 0-168 hours after the start of the first cisplatin administration
Cisplatin
+9 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Treatment group AExperimental Treatment1 Intervention
HR20013 for injection + simulant of fosaprepitant dimeglumine for injection + simulant of palonosetron hydrochloride injection + dexamethasone
Group II: Treatment group BActive Control1 Intervention
simulant of HR20013 for injection + fosaprepitant dimeglumine for injection + palonosetron hydrochloride injection + dexamethasone + simulant of dexamethasone
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HR20013 for injection；dexamethasone
2022
Completed Phase 3
~760

Find a Location

Who is running the clinical trial?

Fujian Shengdi Pharmaceutical Co., Ltd.Lead Sponsor
25 Previous Clinical Trials
3,585 Total Patients Enrolled
~259 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top